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Understanding the physiological processes that underlie autoimmune
disorders and identifying biomarkers to predict their onset are two pressing
issues that need to be thoroughly sorted out by careful thought when analyzing
these diseases. Type 1 diabetes (T1D) is a typical example of such diseases. It
is mediated by autoreactive cytotoxic CD4+ and CD8+ T-cells that infiltrate
the pancreatic islets of Langerhans and destroy insulin-secreting β-cells,
leading to abnormal levels of glucose in affected individuals. The disease is
also associated with a series of islet-specific autoantibodies that appear in
high-risk subjects (HRS) several years prior to the onset of diabetes-related
symptoms. It has been suggested that T1D is relapsing-remitting in nature and
that islet-specific autoantibodies released by lymphocytic B-cells are detectable
at different stages of the disease, depending on their binding affinity (the
higher, the earlier they appear). The multifaceted nature of this disease and its
intrinsic complexity make this disease very difficult to analyze experimentally
as a whole. The use of quantitative methods, in the form of mathematical
models and computational tools, to examine the disease has been a very
powerful tool in providing predictions and insights about the underlying
mechanism(s) regulating its onset and development. Furthermore, the models
developed may have prognostic implications by aiding in the enrollment of
HRS into trials for T1D prevention. In this review, we summarize recent
advances made in determining T- and B-cell involvement in T1D using these
quantitative approaches and delineate areas where mathematical modeling
can make further contributions in unraveling certain aspect of this disease.
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There are diverse autoimmune disorders that affect
human health; type 1 diabetes (T1D) in humans
and animal models such as the non-obese diabetic
(NOD) mouse, is one of these diseases that target
insulin-secreting β-cells in the pancreatic islets of
Langerhans. There is general agreement in the scientific
community that the disease is triggered by various
factors in genetically predisposed individuals, that it is
mediated by autoreactive β-cell-specific helper CD4+
and cytotoxic CD8+ T-lymphocytes that infiltrate
the islets and destroy up to 90% of the total β-cell
population (1–5) The destruction of β-cells ultimately
leads to the reduction of insulin secretion and
eventually the induction of abnormally high levels of
blood glucose in these individuals, i.e., clinical diabetes.
It has been hypothesized that (i) reduced expression of
self-antigen(s) in the thymus or extrathymic lymphoid
organs may lead to T1D by impairing negative selection
(6–8); and that (ii) defective clearance of apoptotic β-
cells by macrophages is the main trigger of this disease
(9–11). The subsequent activation and recruitment of
T-cells to the islets, along with the increased release of
proinflammatory cytokines, granzyme B, and perforin
by these immune cells (12, 13), eventually drive β-cell
destruction and increase the workload on surviving
β-cells. This, in turn, is suggested to elevate stress in the
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endoplasmic reticulum (ER), the compartment where
various proteins including insulin are synthesized,
exacerbating β-cell loss (14–16).
Naïve T-cells that leave the thymus, upon the failure
of negative selection, are activated and differentiated
into effector T-cells in the lymph nodes by antigen
presenting cells (APCs) that express islet-specific
autoantigens. Activation of CD8+ and CD4+ T-cells is
determined by T-cell receptor (TCR) interaction with
peptide-major histocompatibility complexes (pMHC)
class I (17) and class II (18), respectively, on APCs.
T-cell recognition of β-cells uses similar mechanisms,
requiring TCR interaction with pMHC class I, and
perhaps class II (19), molecules on the surface of β-
cells. The polyclonal nature of the immune responses
against multiple autoantigens (20) along with the
broad spectrum of avidities (a measure of TCR-
binding affinity) associated with each autoantigenic
specificity make this disease a very complex one to
analyze (Fig. 1). In fact, during T1D progression,
autoreactive T-cells undergo a process of ‘avidity
maturation’ (3, 20, 21), reflecting an increase in the
avidity of T-cells during the course of the autoimmune
response, and signifying a gain in their pathogenic
potential. This process is regulated by both T-cell
competition and tolerance (20). All these factors
make identifying and designing therapeutic strategies
for the disease, such as the monoclonal antibody-
based immunosuppressive approaches (22–24) and
autoimmune-specific nanovaccines (25, 26), a very
challenging task.
Furthermore, in T1D, islet autoantibodies manu-
factured by mature B-cells of the immune system are
directed against one or more host self-proteins and can
serve as reliable surrogate predictive markers of the dis-
ease (27–31). The measurement of these autoantibodies
is now a clear prerequisite in screening for individuals
at risk of developing hyperglycemia and clinical dia-
betes requiring insulin for treatment, and one of the
most potent risk determinants (32–35). It has been
proposed that the presence of two or more autoanti-
bodies to islet autoantigens [such as insulin, glutamic
acid decarboxylase 65 (GAD65), or islet-autoantigen
2 (I-A2)] should be used as entry criteria for interven-
tion trials (36, 37). However, the design of these trials,
such as TrialNet, should be based on the understand-
ing that over 50% of relatives who were positive for
autoantibodies might not develop insulin requirement
within 5 yr (27, 28, 38, 39). Therefore, predicting the
rate of progression to clinical disease is still difficult
and requires alternative ways to assist in the screening
process. Several well-defined epidemiological studies
are currently available around the world and these at
risk populations represent the groundwork from which
antibody risk determinants can be applied and refined.
These studies include the Bart’s Windsor study (40),
the Joslin-Denver (35, 41, 42), Pittsburgh (43), Seattle
(44), Gainesville (45), and a number of other impor-
tant family studies (46, 47). T1D is the quintessential
model for the application of autoantibody markers in
the prediction of a selective immune-mediated tissue
damage, and this concept can be theoretically extended
to other chronic autoimmune diseases.
Developing predictive mathematical models to
understand the immunological processes underlying
the onset and progression of T1D is an alternative
and powerful method to achieve this goal. Typically,
these models are expressed as ordinary differential
equations (ODEs) that describe the temporal dynamics
of the population sizes of immune cells, as well as
the concentrations of autoantigens and autoantibodies
implicated in the disease. They are either analyzed
theoretically using mathematical methods or simulated
numerically using computational tools to examine
their short- and long-term (steady-state) behavior. It
is anticipated that these models, when perfected and
validated against experimental data, can eventually
serve as diagnostic tool(s) of the disease in clinical
settings.
In this review, we summarize recent findings
associated with MHC class II genetic susceptibility
in T1D, and present an overview of the literature on
modeling different aspects of the disease. We highlight
how these mathematical models were utilized to make
predictions and important insights about the various
components implicated in the disease. We also propose
new directions in the investigation of T1D progression
and treatment using these theoretical approaches.
Single pMHC class II complex is critical
for T1D
Peptide binding and presentation by MHC class II
is essential for CD4+ T-cell activation. Peptides are
typically anchored onto the MHC class II binding
cleft through their amino acid side chains at four
positions, termed pockets P1, P4, P6, and P9, which
also interact with the flanking alpha helices of the
MHC molecule to stabilize the pMHC complex (48).
Comparison of MHC class II alleles in genome-
wide single-nucleotide polymorphism (SNP) studies
showed surprisingly conserved MHC sequences with
the exception of a few amino acid alterations in the
flanking alpha helices. Disease-promoting alleles of
the gene encoding for the human MHC class II β
chain have amino acid alterations characterized by the
replacement of a positively charged residue, such as
aspartic acid (ASP) near the P9 position of the peptide-
binding pocket, with a non-charged amino acid serine
(SER) or alanine (ALA) (49, 50). This results in a
net-positively charged P9 pocket, as SER and ALA
cannot neutralize the charge imparted by the opposing
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Fig. 1. (A) A scheme showing the effect of high/intermediate/low avidity/affinity T-cell receptor–peptide-major histocompatibility complexes
(TCR-pMHC) interaction. High affinity/avidity interaction leads to deletion of most autoreactive T-cells, creating a T-cell repertoire that
is low in pathogenic and high in regulatory T-cells (Tregs), resulting in healthy state without islet destruction. Intermediate affinity/avidity
interaction results in a T-cell repertoire contain not only a higher portion of pathogenic T-cells, but also a high number of Tregs. This results
in limited islet destruction, because the Tregs limit the destructive effects of the pathogenic T-cells. Low avidity/affinity interaction results
in T-cell pool containing many autoreactive T-cells with few Tregs. This results in autoimmune state where most islets are destroyed. (B) A
scheme showing the various components of the autoimmune response in T1D including the Copenhagen model. The uptake of β-cell specific
proteins by antigen presenting cells (APCs) triggers APC recruitment and activation. This in turn leads to the activation of various classes of
islet-specific CD4+ and CD8+ T-cells [i.e., Th-lymphocytes, Tregs and autoregulatory T-cells (Taut)], as well as B-cells. High-avidity cytotoxic
T-lymphocytes destroy β-cells by either secreting harmful cytokines or by inducing apoptosis via cell-to-cell contact. Mature B-cells release
islet-specific autoantibodies that may appear prior to disease onset.
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alpha helix. Alignment of the murine disease-protective
I-Aβ chain and the disease-promoting counterpart I-
Aβg7 (the only MHC class II chain in NOD mice)
show similar amino acid alterations. Interestingly, it
was shown in studies of MHC class II polymorphism
that transgene expression of the protective I-Aβ allele
in NOD mice completely ablated the development
of diabetes (51).
It is expected that modifying the affinity of peptide
binding can have significant implications on other
aspects of MHC class II mediated processes. For
example, it was demonstrated that disease-promoting
MHC class II molecules bind a different set of
peptides than those that bind to the disease-protective
MHCs, with the former favoring the binding (with
high affinity) of peptides carrying an acidic side
chain at the C-terminus, thereby impairing their
binding to certain self-peptides (52, 53). Therefore,
it was proposed (52) that negative selection in the
thymus is governed by the affinity/avidity of the
interaction between pMHC and TCR (Fig. 1A). High
affinity interaction of autoreactive T-cells to MHC
presented by APCs and epithelial cells in the medulla
of the thymus promotes deletion through negative
selection and/or the development of regulatory T-
cells (Tregs). These processes dampen the autoimmune
reaction by reducing the size of the pathogenic T-
cell population and imparting suppressor function
to those that survive. The change in peptide affinity
and peptide-binding repertoire in disease-promoting
MHCs is thought to decrease the affinity/avidity of
this interaction and thus compromise thymic negative
selection, leading to the escape of autoreactive T-cells
that lack suppressor function from the thymus. In
the pancreas, the increased exposure to self-peptides
eventually leads to the activation of islet-reactive T-
cells and the demise of β-cells.
This hypothesis was supported by studies on the
binding of a dominant autoantigenic peptide in NOD
mice: the insulin β-chain (B:12–23). It is known
that this 12 amino acid peptide can bind the NOD
MHC class II I-Aβg7 in four positions or ‘registers’.
Binding in register 3, where B:14–22 are anchored
in the peptide-binding pocket, is the least favorable
biochemically due to the charge clash between arginine
(ARG) and the positively charged P9 pocket of I-
Aβg7. Surprisingly, binding at this register was found
to be most immunogenic to Barbara Davis Center
for Childhood Diabetes (BDC) 12–4.1 T-cells, the
cognate T-cell against insulin B:12–23 (54). It is
possible that the low-affinity binding can cause poor
or low presentation during negative selection, allowing
pathogenic T-cells recognizing self-peptides, to survive.
Further, it was shown that T-cells recognizing B:12–23
in register 3 are pathogenic while populations that
recognize the same peptide presented in other, more
favored registers, are protective and non-disease-
promoting (55).
Insulin, despite being one of the primary antigenic
targets for T-cells in NOD mice, can only stimulate
anti-B:12–23 T-cells when presented by islet-resident
APCs (14, 56). In addition, owing to the low-binding
affinity of B:12–23 peptide to the immunogenic
register, the physiological concentration of insulin
in circulation is not enough to lead to any immune
stimulation even in NOD mice. In the pancreas,
however, APCs can engulf vast amounts of insulin
produced by β-cells and present antigens above the
threshold of activation for autoreactive T-cells.
Most proteins undergo post-translational modifica-
tions (PTMs), a process which has shown some associ-
ation with autoimmunity. Some PTMs can create new
autoantigens or mask antigens normally recognized
by the immune system. Differential antigen processing
that may result from the PTMs is another process that
can affect the onset of autoimmune response. While no
direct evidence of PTMs in T1D has been observed,
discussion of the effect of PTMs in the context of other
autoimmune diseases, such as rheumatoid arthritis,
multiple sclerosis, and celiac disease, can be found in
other reviews (57, 58).
Modeling the role of APCs in T1D
The involvement of APCs, including macrophages, in
the onset of T1D remains an outstanding question.
It has been suggested that these cells play an
important role in phagocytizing dead β-cells that
have been destroyed because of external or internal
environmental factors, such as the naturally occurring
β-cell apoptotic wave observed in rodents and primates
during the neonatal period (59, 60). A mechanism
underlying this autoimmune process was first proposed
by Nerup et al. (61, 62) in the Copenhagen model
describing the onset and progression of this disease (see
Fig. 1B). The model conjectured that protein uptake
by APCs trigger autoantigen processing, pMHC class
II expression, and further APC recruitment and
activation. This in turn caused monokine secretion
by activated APCs, such as interleukin (IL)-1 and
tumor necrosis factor (TNF), as well as upregulation
of costimulatory signal(s), leading to the induction
of cytokine secretion from islet-specific CD4+ helper
T-cells (Th)-lymphocytes, such as IFN, and further
APC activation. It was then hypothesized that β-
cell destruction (or apoptosis) is caused by either the
induction of free radicals by cytotoxic IL-1 release
from APCs and/or the upregulation of Fas receptor
(a member of the tumor necrosis factor receptor
superfamily) expression on β-cell surface and its
increased interaction with Fas ligand on infiltrating
lymphocytes. One would then expect that these two
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latter processes amplify the autoimmune response and
cause further damage to the tissue.
A mathematical formulation based on the Copen-
hagen model was developed by Freiesleben De Blasio
et al. (63) to test the model and determine if certain
components are predominantly responsible for trig-
gering T1D. The model was described in the form of
ODEs portraying the rate of change of two interacting
populations of macrophages, a resting population not
expressing islet-specific pMHCs and an active popu-
lation expressing pMHCs, along with one population
of Th-lymphocytes, and the total expression level of
pMHCs. The model showed that T1D susceptibil-
ity is due to dynamic instability in the system as a
whole, rather than one single etiological trigger. In
fact, it was demonstrated that in healthy conditions,
i.e., in the non-disease state, the population sizes of all
these immune cells ultimately vanish, but under certain
immunological conditions, generated by applying per-
turbations to the parameters of the system, the healthy
state loses stability and the disease is manifested.
Further extensions of the Freiesleben De Blasio
model were subsequently reported (64, 65). More
specifically, a direct description of β-cells was included
(64), instead of considering only the expression level
of autoantigen(s). In this study, it was shown that
disease dynamics of T1D critically depend on the
rate of β-cell turnover (i.e., the difference between
β-cell replication/neogenesis and death), which in
turn depends on the organ developmental stage of
the pancreas. As such, it was suggested that the
slow and fast turnover of β-cells are responsible for
the age-dependent heterogeneity observed in T1D
pathology, an outcome that is in agreement with
clinical observations. The oscillatory decline of β-cell
number to zero, however, made this modeling study
less physiological. A different mathematical model (65)
combined the Freiesleben De Blasio model with the
β-cell model described glucose and insulin effects on β-
cell mass (66). The end result was a model of early
stages of the disease that was composed of both
an autoimmune and metabolic components. When
examining the degenerative and autoimmune-induced
loss of β-cells, the study found that depending on
the degree of regulation, autoimmunity may play a
protective role in the initial response to stressors.
Although the Freiesleben De Blasio model (63) and
these follow-up studies (64–66) provided important
qualitative insights about the mechanisms underlying
susceptibility, they were mostly phenomenological,
and represented only an approximation of the real
physiological system. For these reasons, several models
were subsequently developed to address certain aspects
of macrophage complicity in the initiation of the
disease (9–11). One of these aspects is the defective
clearance of apoptotic β-cells by macrophages, which
was further analyzed by developing several Markov
state models (67, 68) that described the process of
macrophage encounter and engulfment of up to N
(=7 or 12) apoptotic cells (Fig. 2). Each state in these
models represented the class of macrophages (Mi) with
a given number (i≤N) of engulfed apoptotic cells inside
them, and the transitions between them were assigned
the rate constants ka, ke, and kd. The main focus of
both of these studies was to determine what properties
of macrophage phagocytosis (including engulfment,
degradation, and/or activation) are altered in NOD
mice prone to T1D in comparison with wild-type mice,
and to quantify the level of impairment. According
to these studies, it was found that macrophages from
normal (Balb/c) mice engulf apoptotic cells 2.6–5.5
times faster than those in NOD mice (67, 68), and that
the digestion of apoptotic cells is not only serial (i.e.,
the backward digestion rate in Fig. 2 is constant kd),
but also at least two times slower in NOD than in
Balb/c macrophages (67). Interestingly, an activation
step and an acceleration in subsequent engulfment steps
were found to be exhibited in both strains, except that
they are smaller in NOD than in Balb/c macrophages
(67). These results were obtained by applying steady-
state analysis and fitting model simulations to in vitro
macrophage feeding experimental data that included
two measurable quantities: the percent of macrophages
that have visible engulfed cells and the average number
of engulfed cells per 100 macrophages.
These results were further tested (69) by considering
and quantifying variants of the Freiesleben De Blasio
model (63) based on parameter values obtained for
NOD and (normal) Balb/c mice (68). The goal was
to determine whether macrophage defects alone are
sufficient for triggering chronic inflammation, or if the
apoptotic wave of β-cells (59, 60) is also necessary for
initiating T-cell priming associated with full-blown
disease. The results revealed that the Freiesleben
De Blasio model cannot quantitatively explain
these observed results within biologically reasonable
parameters, even if other strain-specific variations are
included (e.g., differences in macrophage-induced rate
of damage to β-cells). However, when the model
was modified, by taking into account the ability
of necrotic β-cells, i.e., β-cells destroyed by harmful
monokines secreted by activated NOD macrophages
that failed to promptly remove apoptotic β-cells
(70), the results were qualitatively and quantitatively
consistent with the observed differences between
NOD and Balb/c macrophages. In other words,
it was shown that the apoptotic wave can trigger
escalating inflammatory response in NOD, but not
Balb/c mice. One important feature in this study was
the inclusion of a more physiologically reasonable
assumption regarding monokines namely that they
induce apoptosis in β-cells with saturating kinetics.
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Fig. 2. Two possible Markov models describing the dynamics of phagocytosis in macrophages. Macrophages may have up to N undigested
apoptotic cells inside them. Both models require an activation step of naïve macrophages with an activation rate constant ka. The forward
transitions (excluding the first step), representing the engulfment of new apoptotic cells, occur with a rate constant ke, whereas the backward
transitions, representing digestion, occur with a rate constant kd. (A) The activation step is assumed reversible. (B) The activation step is
assumed irreversible.
A molecular-based model, also in the form of
ODEs, describing the processing of β-cell specific
proteins in APCs, particularly macrophages, was
also developed to examine why certain proteins,
such as islet-specific glucose-6-phosphatase catalytic
subunit-related protein (IGRP), take on a dominant
autoantigenic role, whereas many others do not (71).
This model was based on the defective ribosomal
product (DRiP) hypothesis (72), suggesting that
significant fraction (over 30%) of proteins are
degraded by proteasomes shortly after their synthesis,
presumably due in large part to their inability to achieve
a functional state. The model analyzed and quantified
the interplay between antigenic stability and pMHC
class I production efficiency in determining pathogenic
potential of autoantigenic proteins, including IGRP,
in the context of autoimmune T1D. The model
examined proteins allocated to rapidly degraded vs.
stable functional pools, both contributing (with relative
efficiency η) to pMHC presentation on a β-cell,
as well as to cross-presentation on an APC. By
applying local stability analysis on the model, the study
concluded that autoantigenicity (the ability to elicit T-
cell activation) and pathogenicity (the ability to cause
β-cell lysis) are not equivalent, and that pathogenicity
peaks at low-to-moderate levels of autoantigenicity.
The intriguing outcomes of this study, considered to
be the first to explore the link of the DRiP hypothesis
to autoimmunity, remain untested experimentally.
Modeling T-cell dynamics during T1D
progression
Over the last few years, several mathematical models
of T1D progression have been also developed in the
form of ODEs. The two main goals in conducting
these quantitative studies were to explore possible
mechanisms underlying the role of CD4+ and
CD8+ effector and (auto-) regulatory T-cells in
diabetogenesis, as well as to analyze and optimize
the effect of certain interventional therapies to T1D.
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Fig. 3. Cyclic fluctuations in the pool size of effector T-cells with a given autoantigenic specificity, as predicted by the model (see reference
(80)). (A) Periodic damped oscillations with high frequency. (B) Low-frequency cyclic waves with few peaks that correlate with the number of
clones considered in the model.
Modeling studies of T1D progression initially
started with the analysis of why soluble peptides,
such as the protein fragment IGRP206–214 intended
to induce peptide-specific T-cell tolerance (73–75),
mostly failed to blunt poly-specific autoimmune
responses. For example, it was shown that despite
effectively deleting the IGRP206–214-reactive CD8+
pool, the administration of a mimotope of IGRP206–214
to NOD mice does not protect them from T1D
(20, 73). A model consisting of (two) competing
clones of T-cells, with various levels of avidities,
showed that the success or failure of this treatment
depends on how dose and peptide affinity alter T-
cell activation, proliferation, and differentiation (76).
More specifically, the model revealed that peptide
treatment can lead to either an increase in the imbalance
between competing IGRP206–214-reactive T-cell clones,
favoring rapid takeover of high-avidity clones, or the
deletion of all IGRP206–214-reactive clones, thereby
creating a vacuum that promotes the recruitment
of pathogenic subdominant specificities (also called
the switch phenomenon). In the case of successful
treatment, the model predicted that the imbalance
between the competing clones of IGRP206–214-reactive
T-cells fosters the expansion and recruitment of low-
avidity (non-pathogenic) clones instead.
This study was later extended to examine why
IGRP206–214-reactive CD8+ T-cells in NOD mice
eventually develop diabetes exhibit cyclic fluctuations
in their proportion relative to other CD8+ T-cells (77).
This phenomenon was investigated quantitatively and
phenomenologically by using a population model of
T-cells, consisting of active, memory and effector cells,
as well as β-cells (78). The study showed that these
limited number of cycles (that exhibited an increase
in period, nadir and amplitude at each cycle) occur
when the activation of effector T-cells is assumed
to increase and the production of memory cells
to decline with the autoantigen level induced by a
reduction in the clearance of apoptotic debris (67).
Although the study was very insightful in providing a
plausible mechanism for these oscillations, there were
two major drawbacks; namely, the severe sensitivity
of the oscillations produced by the model to small
perturbations in the initial number of T-cells at the
start of the autoimmune attack, and the inability of
the model to reproduce the increase in the nadir at
each cycle. Given that the presence of these oscillations
is consistent with the relapsing-remitting nature of
T1D (79), our recent analysis revealed that interclonal
and intraclonal T-cell competition (possessing various
levels of avidity and autoantigen specificity) are the
driving force for generating such transient fluctuations
(Fig. 3). Using a model that is structurally similar
to another previously reported (78), we discovered
that, in the presence of four competing subclones with
two antigenic specificities and four ascending levels of
avidity, robust fluctuations in the number of T-cells,
consistent with the observed experimental behavior,
are produced as either dampened periodic cycles with
relatively short periods (panel A), or transient (two)
waves with long periods (panel B). Details of this study
are available in (80).
Recent studies by Santamaria et al. (5, 25,
26, 81) demonstrated that low-avidity autoreactive
CD8+ T-cells spontaneously differentiate during
T1D progression into non-pathogenic memory
autoregulatory T-cells specific for particular Islet
Antigens. It was suggested that the expansion of this
population to therapeutic levels can blunt T1D in NOD
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mice. This could be performed using nanoparticles
(NP) coated with pMHC class I complexes that
selectively induce the expansion, in an antigen-
specific manner, of low-avidity memory autoregulatory
CD8+ T-cells (25, 26). These CD8+ T-cells suppress
diabetogenic, islet-specific effector T-cells in the
pancreatic lymph nodes. As a result, treatment with NP
could both prevent T1D and restore normoglycemia.
Modeling these aspects of the autoimmune response
and optimizing the therapeutic effects of NPs have
become a fascinating new direction in the field
of modeling autoimmune T1D. More specifically,
the protective role of the low-avidity autoregulatory
memory CD8+ T-cells was investigated by developing
a series of differential equation models for (i) the
interactions of low-avidity autoregulatory and high-
avidity effector IGRP206–214-reactive T-cells, (ii) the
effect of APCs in T-cell activation, and (iii) the positive
feedback from killed β-cells (82). The models were
used to test two independent hypotheses supported
by in vivo and in vitro experimental data. The first
hypothesis suggested that the memory T-cell pool
crowds islets and outcompetes effector high-avidity
CD8+ T-cells, whereas the second hypothesis suggested
that APCs get deleted by this memory T-cell pool
(26). The results showed that the steady-state level
of β-cells in the former case increases much more
rapidly (see Fig. 4), an outcome incompatible with
data, strongly suggesting that the latter hypothesis
is more likely. These models were then used to
examine the influence of various treatment strategies
based on NPs coated with β-cell-specific pMHC and
targeted towards expanding autoregulatory T-cells, on
the progression of the disease. The model revealed
that progressive accumulation of memory T-cells
during disease progression makes treatments aimed at
expanding these protective T-cell types more effective
close to or at the onset of clinical disease.
This study was then expanded to a protocol, based
on a data fitting method called the genetic algorithm,
which was devised for providing parameters for the
model using in vivo experimental data obtained from
NOD mice (83, 84). Heterogeneity along with the
type and paucity of data made, and continue to
make, this a challenge. The models developed in
these studies included a class of subdominant non-
IGRP206–214-reactive T-cells in addition to those clones
considered (82). These models were used to understand
the dynamics of competition between T-cell pools and
their role in inducing the switch phenomenon (Fig. 5),
to predict the outcome of pMHC-NP therapy, and
as a guide to optimize treatment frequency, dose and
pMHC-NP valency (the expression level of pMHC
on NPs). It was shown, e.g., that increasing the
frequency of injection is therapeutically more effective
than increasing the dose (83) and that a moderate
Fig. 4. The steady-state level of the fraction of surviving β-cells (βss)
predicted by the model (see reference (82)) based on two independent
hypotheses: (A) memory autoregulatory T-cells crowd the islets
and block effector T-cells from reaching β-cells; and (B) memory
autoregulatory T-cells kill antigen presenting cells (APCs). Solid
lines represent the physiologically attainable steady states, whereas
dashed lines represent the physiologically unattainable steady states.
The horizontal solid lines in both panels represent the healthy and
unaltered βss = 1, in the absence of autoimmunity, whereas the other
solid lines represent βss< 1 in the presence of autoimmunity. Notice
that increasing the proliferation rate of memory autoregulatory T-
cells in (A) causes a rapid rise in βss in the autoimmune case, whereas
decreasing the scaled pool size of APCs induces a slow increase,
suggesting that the latter is more physiological.
increase (≥1.6-fold) in the NP-dependent expansion
rate of autoregulatory T-cells leads to a significant
increase in the efficacy and the area corresponding to
the effective treatment regimen provided that NP dose
is ≥8 μg (84). By taking into account the underlying
hypothesis that the expansion of autoregulatory T-
cells and deletion of autoantigen-loaded APCs by
these T-cells are biphasic (increases at low NP doses
and decreases at high NP doses) (84), resonance-like
behavior was observed in these models, and ranges in
pMHC-NP valency, exhibiting no autoimmunity, were
also identified. The importance of the models presented
in both of these studies arise from the fact that they
could be generalized to other autoimmune disorders
and could eventually serve as computational tools to
understand and optimize pMHC-NP-based therapies
in these diseases.
A limited number of models examining the role
of (CD4+FOXP3+CD25+) Tregs in the progression of
T1D have also been developed. A mathematical model
that takes into account the dynamics of functional
and dysfunctional β-cells, Tregs, and pathogenic T-
cells was presented (85) to understand the impact
of altering the balance between pathogenic T cells
mediating T1D and Tregs on autoimmunity (86). The
model provided that quantitative information on how
the ratios of pathogenic T-cells to Tregs, as well as
other kinetic parameters, affect the timing of disease
onset and progression. The drawback of this study was
the assumption that Tregs, contrary to experimental
evidence, secrete IL-2. Another similar study that
extended the Freiesleben De Blasio model by including
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Fig. 5. Increasing the proliferation rate of memory autoregulatory
T-cells (Taut) (denoted by m) may lead to the switch phenomenon. (A)
At a low Taut proliferation rate, the level of islet-specific glucose-6-
phosphatase catalytic subunit-related protein (IGRP206–214)-reactive
effector T-cells is elevated. (B) At a high Taut proliferation rate, the
total level of other subdominant effector T-cells is elevated.
the dynamics of Tregs was also conducted to address
the same questions (87).
Models of islet autoantibodies
Autoimmune T1D is associated with a series of
conventional and novel anti-islet autoantibodies,
produced by mature B-cells that may be present
for years in high-risk subjects (HRS), i.e., first
degree relatives of T1D patients, prior to the onset
of hyperglycemia. It has been suggested (79) that
these autoantibodies accumulate sequentially and
gradually during epitope spreading associated with
disease progression. Recent studies revealed that novel
autoantibodies, such as those against the extracellular
domain of I-A2, have a success rate of 100% in
predicting disease onset in HRS within 10 yr of follow
up, unlike conventional autoantibodies (e.g., against
GAD65) that require 15 yr of follow up for only 74%
predictive rate (i.e., 74% of HRS develop the disease
within 15 yr) (27, 34). The former group was labeled
as fast progressors and the latter slow progressors.
Using data collected over at least 13 yr from cohorts
of children at risk of T1D in various countries, a new
detailed study (35) revealed that T1D incidence at
10-yr follow-up after seroconversion in children with
multiple islet autoantibodies is 69.7%, with a single islet
autoantibody is 14.5%, and with no islet autoantibodies
is 0.4% (by the age of 15 for the latter group). It was also
found that T1D progression in children with multiple
islet autoantibodies is age-dependent, being faster in
children who seroconverted at less than 3 years of age
than children who seroconverted at 3 yr or older.
The first modeling attempt in analyzing these
intriguing experimental results was quantitatively
performed in the Tregs study described in the previous
section (85). In this model, the production of
pathogenic T-cells was assumed to be the sum of a
sequence of step functions that correlated with the
sequential appearance of autoantibodies during T1D.
Although the study did not consider the dynamic
behavior of autoantibodies and B-cells that produce
them, it provided some insights into how β-cell loss
is manifested when 1–3 autoantibodies appear in
circulation.
A subsequent study was then performed to
analyze more systematically the role of islet-specific
autoantibodies in predicting disease onset in HRS (83).
The main goal of the study was to test the hypothesis
that heterogeneity in both TCR-binding affinity (T-cell
avidity) and killing efficacy (i.e., the rate of T-cell
dependent β-cell lysis) is responsible for inducing
clinical differences between fast and slow progressors of
T1D. A series of competition-based population models,
in the form of ODEs, that accounted for T-cell, B-
cell, β-cell, autoantigen, and autoantibody dynamics
were presented in this study. The models revealed that
low-avidity, low-efficacy T-cell clones can compete
with high-avidity, high-efficacy clones to confer a
degree of protection. Moreover, by assuming that T-
and B-cell avidities are correlated (i.e., the binding
affinity of TCRs and autoantibodies are correlated), the
study showed that, on average (over a heterogeneous
population of individuals, each represented by a set
of parameters with physiologically reasonable values),
an increase in avidity leads to faster β-cell destruction
and rise in islet-autoantibodies over time, but the peak
amplitude of the autoantibody titer is most pronounced
at intermediate avidities (see Fig. 6). Interestingly,
when both T-cell avidity and killing efficacy were
assumed to be very high, and perhaps higher than their
physiological limits, the autoantibody level remained
undetectable throughout disease progression due to
the lack of peptide accumulation necessary for T-
and B-cell activation. This study was then extended
by considering multiple clones of T- and B-cells to
show how competition induces cyclic fluctuations in
T-cells, underlying relapse-remission in T1D, and how
these fluctuations regulate sequential accumulation of
islet-autoantibodies (80).
Discussion and future directions
Understanding autoimmune responses in the context
of T1D using experimental tools can be very
daunting. With the emergence of the field of
computational biology and non-linear dynamics,
the complex systems regulating these responses
can be analyzed theoretically. Examining various
aspects of these immunological systems by developing
mathematical models and designing computational
tools to investigate them represents an alternative
and cost-effective way to do so. These models not
only provide important insights into the cellular and
molecular processes occurring in these systems, but
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Fig. 6. Increasing T-cell avidity on average leads to a faster β-cell destruction, a faster rise in cognate autoantibodies, and a biphasic response
in the peak amplitude of the autoantibody titer. Time evolution of (A) the average pool sizes of high (black), intermediate (dark gray), and
low (light gray) avidity T-cells. (B) Fraction of surviving β-cells in the presence of high (black), intermediate (dark gray), and low (light gray)
avidity T-cells. (C) Scaled titer level of cognate high (black), intermediate (dark gray), and low (light gray) affinity autoantibodies.
they also raise intriguing mathematical questions that
are tackled numerically using computational tools
or theoretically using methods of non-linear stability
analysis. In this review, we presented a summary of the
most recent advances and major contributions made
using mathematical models to this field.
Several questions associated with T1D onset
and progression were tackled, including the role
of macrophages, pathogenic CD4+ and CD8+
autoreactive T cells, (auto)regulatory T cells, B cell, and
β-cells. The models constructed and used were mostly
ODE models that described the temporal dynamics
of the various factors involved in the processes under
investigation. Although the predictions and insightful
conclusions made by these studies helped direct new
experiments in the field, validating these models against
experimental data collected from animal models and
extending them to human-based data still remain
a challenge. There are, however, several statistical
methods available in the literature that can be
used to probabilistically validate these models and
determine their implications in understanding how
these immunological systems work. Certainly, there are
still many open questions in the field of autoimmunity
and T1D that mathematical modeling could undertake.
The vital role of T-cell avidity in determining the
course of the autoimmune response in T1D is quite
evident experimentally. Typically, in these experi-
mental studies, T-cells are divided into (sub)clones
possessing different levels of avidity that is measured
by their sensitivity to peptide-dependent activation
(88, 89). Fluorescence-activated cell sorting (FACS)
plots in most of these studies, however, show that
(CD4+ and CD8+) T-cells exhibit a whole spectrum of
reactivity to autoantigenic peptides. In other words,
T-cell avidity in the physiological sense is not a discrete
quantity, but more likely a continuum that covers
a whole range of values. In all of the T-cell models
developed so far to analyze the T1D progression,
avidity was taken to be discrete, generating distinct
classes of T-cell clones and ODEs to describe them
dynamically. It will be interesting to extend such mod-
els to integro-differential equations by making avidity
an independent variable in order to generate more
physiological models that can be used to examine the
polyclonal nature of T1D, determine the underlying
mechanism of avidity maturation, and explore ways
to manipulate the disease for therapeutic purposes.
Another important step in the study of T1D using
these quantitative approaches is to combine models of
disease initiation (describing macrophage involvement)
with models of disease progression (describing the
involvement of the adaptive immune system) to see
how they influence each other and how they affect
β-cell destruction and ER stress including the unfolded
protein response (16). The difficulty of achieving this
experimentally, especially in vivo, makes mathematical
modeling a very attractive approach to explore the
interaction between these two components of the
disease at various stages. Dealing with the complexity
of the model will certainly be a challenge, but the fact
that the dynamics of its different components are well
understood makes this step feasible.
As indicated in the review, two important factors
have not been addressed so far by the modeling
community; namely, the effect of various cytokines
in T1D onset and progression along with the role of
age in determining the timing of seroconversion and
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the severity of the disease. The magnitude of β-cell
destruction will depend on the velocity of the feedback
circuit between APCs and the Th-lymphocytes, i.e., the
efficacy of antigen transport/presentation/recognition,
on the magnitude and type of cytokine production, and
on the capacity of β-cell defense mechanisms during the
cytokine exposure. B-cell activation and autoantibody
production during these processes will also require the
involvement of certain cytokines. Developing models
that explicitly describe the dynamics of cytokines
would be an important step towards deciphering their
function in T1D and in defining the role of age in the
autoimmune response.
It should be mentioned here that there exists a
large volume of modeling papers that focus on the
electrophysiological properties of β-cells, and how they
are affected in disease conditions. We refer the reader
to a recent review on this topic by Ajmera et al. for
more details (90).
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